Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
08:00am, Thursday, 30'th Jul 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
08:30am, Wednesday, 29'th Jul 2026
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance
PolyPid, Azurity sign surgical site infection drug deal
07:31am, Tuesday, 21'st Jul 2026
Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commercialise a drug aimed at preventing surgical site infections in the U.S. and Canada, under which
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
07:30am, Tuesday, 21'st Jul 2026
PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effec
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
08:30am, Monday, 01'st Jun 2026
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
08:30am, Wednesday, 20'th May 2026
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes
PolyPid Q1 Earnings Call Highlights
02:11pm, Wednesday, 13'th May 2026
PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate f
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
12:18pm, Wednesday, 13'th May 2026
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
07:30am, Wednesday, 13'th May 2026
Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETA
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
08:00am, Wednesday, 06'th May 2026
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elev
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PET
BeOne Medicines (NASDAQ:ONC) & PolyPid (NASDAQ:PYPD) Critical Analysis
01:44am, Friday, 17'th Apr 2026
BeOne Medicines (NASDAQ: ONC - Get Free Report) and PolyPid (NASDAQ: PYPD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based o
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
09:15am, Monday, 13'th Apr 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of “Moderate Buy” from Analysts
02:18am, Monday, 13'th Apr 2026
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat.com reports. One inv
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3% – Still a Buy?
01:48am, Friday, 10'th Apr 2026
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report)'s share price shot up 3.3% on Thursday. The company traded as high as $4.37 and last traded at $4.37. 13,903 shares were traded during trading, a decline
